Mazanor
(Mazindol)Phase 2Small molecule
NovartisMazanor is one of 84 small molecule programs targeting Cocaine Abuse. It is currently in Phase 2.
3
Indications
4
Total Trials
0
Active Trials
83
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
102 competitors in Attention Deficit Hyperactivity Disorder
#DrugCompanyPhaseTrials
1Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Provigil
NNuvo Research GmbH
Phase 3
Catapres
Boehringer IngelheimPhase 3
Ambien
PPurdue Pharma LP
Phase 3
OROS Oxybutynin
Johnson & JohnsonPhase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Ritalin
PfizerPhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 2
Adderall-XR
NNew River Pharmaceuticals
Phase 3
Concerta
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Narcolepsy2 trials
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
MAZANOR
NDA NDA017980
Jan 1, 1982
SANOREX
NDA NDA017247
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mazindol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]